Y-90 clivatuzumab tetraxetan - Immunomedics

Drug Profile

Y-90 clivatuzumab tetraxetan - Immunomedics

Alternative Names: 90Y-clivatuzumab tetraxetan; 90Y-hPAM4; 90y-Hpama4; Clivatucyn; Clivatuzumab; Clivatuzumab tetraxetan; Clivatuzumab tetraxetan Y-90; Clivatuzumab Y-90; hPAM4-Cide; hPAM4-DOTA; Humanised monoclonal antibody PAM4 Y-90; IMMU-107; Monoclonal antibody PAM4-Y-90; Pan-Cide; Y-90 clivatuzumab; Yttrium-(90Y) clivatuzumab tetraxetan; Yttrium-90 clivatuzumab tetraxetan; Yttrium-90 labelled monoclonal antibody PAM4

Latest Information Update: 18 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pancreatic cancer

Most Recent Events

  • 18 Jan 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, First-line therapy) in USA and Germany (IV), because not listed on Immunomedics pipeline, January 2018
  • 18 Jan 2018 Discontinued - Phase-III for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Poland, France, Belgium, Israel, Canada, Spain, Austria and USA (IV), further to negative results from the PANCRIT® 1 trial
  • 14 Mar 2016 Immunomedics terminates the PANCRIT-1 phase III trial in Pancreatic cancer in Austria, Belgium, Canada, France, Israel, Poland, Spain and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top